Anixa Biosciences Inc (ANIX) stock
ANIXNasdaqPharmaceutical PreparationsFiscal year ends October 31
$2.71+0.04 (+1.50%)
Close on Nov 18, 2026Market cap $94.21MP/E –Yield –
Anixa Biosciences revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Anixa Biosciences's revenue for the twelve months ending Oct 31, 2023 was $210.00K. For fiscal 2024 it was $210.00K, up 0.0% from the year before. Over ten years it grew -13.9% a year on average. The highest annual figure on record is $9.26M in fiscal 2015.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Oct 31, 2024 | $210.00K | 0.0% |
| FY2023 | Oct 31, 2023 | $210.00K | -59.0% |
| FY2021 | Oct 31, 2021 | $512.00K | +104.8% |
| FY2019 | Oct 31, 2019 | $250.00K | -77.5% |
| FY2018 | Oct 31, 2018 | $1.11M | +206.9% |
| FY2017 | Oct 31, 2017 | $362.50K | +20.8% |
| FY2016 | Oct 31, 2016 | $300.00K | -96.8% |
| FY2015 | Oct 31, 2015 | $9.26M | +152.4% |
| FY2014 | Oct 31, 2014 | $3.67M | +843.1% |
| FY2013 | Oct 31, 2013 | $388.85K | -58.6% |
| FY2012 | Oct 31, 2012 | $940.01K | -6.3% |
| FY2011 | Oct 31, 2011 | $1.00M | +37.3% |
| FY2010 | Oct 31, 2010 | $730.68K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023CQ3 2023 | Oct 31, 2023 | $0 | -100.0% |
| Q3 FY2023CQ2 2023 | Jul 31, 2023 | $0 | – |
| Q2 FY2023CQ1 2023 | Apr 30, 2023 | $210.00K | – |
| Q2 FY2022CQ1 2022 | Apr 30, 2022 | $0 | – |
| Q1 FY2022CQ4 2021 | Jan 31, 2022 | $513.00K | 0.0% |
| Q4 FY2021CQ3 2021 | Oct 31, 2021 | $0 | – |
| Q3 FY2021CQ2 2021 | Jul 31, 2021 | $0 | – |
| Q2 FY2021CQ1 2021 | Apr 30, 2021 | $0 | -100.0% |
| Q1 FY2021CQ4 2020 | Jan 31, 2021 | $513.00K | – |
| Q4 FY2019CQ3 2019 | Oct 31, 2019 | $0 | -100.0% |
| Q3 FY2019CQ2 2019 | Jul 31, 2019 | $0 | -100.0% |
| Q2 FY2019CQ1 2019 | Apr 30, 2019 | $250.00K | – |
| Q4 FY2018CQ3 2018 | Oct 31, 2018 | $0 | -100.0% |
| Q3 FY2018CQ2 2018 | Jul 31, 2018 | $362.50K | +81.3% |
| Q2 FY2018CQ1 2018 | Apr 30, 2018 | $750.00K | – |
| Q4 FY2017CQ3 2017 | Oct 31, 2017 | $0 | – |
| Q3 FY2017CQ2 2017 | Jul 31, 2017 | $362.50K | – |
| Q4 FY2016CQ3 2016 | Oct 31, 2016 | $200.00K | – |
See a number that looks wrong?